Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”

Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”

Saved in:

Bibliographic Details
Main Author:	Manabu Kato
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	IJU Case Reports
Online Access:	https://doi.org/10.1002/iju5.12805
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases
by: Daisuke Matsumoto, et al.
Published: (2025-01-01)

Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma
by: Christopher G. Fawsitt, et al.
Published: (2025-01-01)

A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib
by: Huaxiang Wang, et al.
Published: (2025-01-01)

Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report
by: Lisha Li, et al.
Published: (2024-12-01)

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial
by: Yaoping Shi, et al.
Published: (2024-12-01)

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2025-01-01)

Pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (PIPER): a phase 2, multicentre, single-arm protocol study in Malaysia
by: Gwo Fuang Ho, et al.
Published: (2024-12-01)

Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data
by: Bogdana Patachi, et al.
Published: (2025-01-01)

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
by: Irina Surovtsova, et al.
Published: (2025-12-01)

Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
by: Amytis Roboubi, et al.
Published: (2025-02-01)

Tumor Lysis Syndrome Due to Pembrolizumab Use in Metastatic Nasopharyngeal Carcinoma
by: Aykut Turhan, et al.
Published: (2024-01-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
by: Chaoneng He, et al.
Published: (2024-01-01)

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
by: Da Xu, et al.
Published: (2025-02-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
by: Xiaohui Zeng, et al.
Published: (2019-12-01)

Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
by: Ilya Tsimafeyeu, et al.
Published: (2024-12-01)

Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
by: Michela Roberto, et al.
Published: (2015-01-01)

Pembrolizumab and axitinib induced pathological complete response in metastatic clear cell renal cell carcinoma with inferior vena cava thrombus: A case report
by: Ryan Wong, et al.
Published: (2025-01-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
by: An Uche, et al.
Published: (2019-01-01)

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
by: Miao-Zhen Qiu, et al.
Published: (2024-12-01)

Efficacy of first-line radiofrequency ablation combined with systemic chemotherapy plus targeted therapy for initially unresectable colorectal liver metastases
by: Yaqing Kong, et al.
Published: (2025-12-01)

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
by: Masato Kikuta, et al.
Published: (2025-01-01)

FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma
by: Yu Ishizuya, et al.
Published: (2025-02-01)

Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
by: Li X, et al.
Published: (2025-01-01)

Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
by: Jun-Wei Wu, et al.
Published: (2024-12-01)

Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01)

Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis
by: Yasuyuki Ikezawa, et al.
Published: (2024-07-01)

A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
by: Kathryn Fleming, et al.
Published: (2018-01-01)

Foot pain as first presenting symptom of renal cell carcinoma, due to metastatic lesion in medial cuneiform
by: Christopher Kleimeyer, et al.
Published: (2024-12-01)

Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre
by: Maria João Santos, et al.
Published: (2025-02-01)

Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma
by: Huimin Zou, et al.
Published: (2025-01-01)

Solitary Contralateral Adrenal Metastases after Nephrectomy for Renal Cell Carcinoma
by: Nikolaos Antoniou, et al.
Published: (2004-01-01)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
by: Jaya Unnithan, et al.
Published: (2007-01-01)

Metastatic Lesion of the Tibia from Renal Cell Carcinoma
by: Piotr Młodożeniec, et al.
Published: (2021-01-01)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
by: Wei Wei, et al.
Published: (2023-08-01)

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01)

Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma
by: Wen-Chen Tang, et al.
Published: (2023-07-01)

Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
by: Tomoki Taniguchi, et al.
Published: (2024-12-01)

Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab
by: Benjamin Müller, et al.
Published: (2024-11-01)

Uncommon metastatic journey: unusual breast metastases of medullary thyroid carcinoma: a case report
by: Saadallah Fatma, et al.
Published: (2025-01-01)